Scarica l'app Stockscreener
4.07
0.99%
0.04
Dopo l'orario di chiusura:
4.07
Precedente Chiudi:
$4.03
Aprire:
$4.02
Volume 24 ore:
94,078
Relative Volume:
0.31
Capitalizzazione di mercato:
$203.12M
Reddito:
$17.63M
Utile/perdita netta:
$-57.71M
Rapporto P/E:
-3.0602
EPS:
-1.33
Flusso di cassa netto:
$-60.45M
1 W Prestazione:
-8.13%
1M Prestazione:
-4.91%
6M Prestazione:
-12.66%
1 anno Prestazione:
-24.07%
Intervallo 1D:
$4.02
$4.08
Intervallo di 1 settimana:
$4.00
$4.60
Portata 52W:
$3.24
$6.71
Scpharmaceuticals Inc Stock (SCPH) Company Profile
Nome
Scpharmaceuticals Inc
Settore
Industria
Telefono
617-517-0730
Indirizzo
25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA
Scpharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-12-01 | Iniziato | Cowen | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-10-11 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-02 | Iniziato | Maxim Group | Buy |
| 2021-09-09 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-10-15 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-30 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
Mostra tutto
Scpharmaceuticals Inc Borsa (SCPH) Ultime notizie
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
KING LUTHER CAPITAL MANAGEMENT CORP Expands Stake in scPharmaceu - GuruFocus.com
TD Cowen reiterates Buy rating on scPharmaceuticals stock, highlights optimism for Furoscix approval - Investing.com India
TD Cowen reiterates Buy rating on scPharmaceuticals stock, highlights optimism for Furoscix approval By Investing.com - Investing.com South Africa
Third Time's The Charm For ScPharma? - RTTNews
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024 - GlobeNewswire
Congestive Heart Failure Treatment Market 2034: Clinical - openPR
The Attractiveness of Investing In scPharmaceuticals Inc (SCPH) is Growing - Knox Daily
Daily Progress: scPharmaceuticals Inc (SCPH) Drop -2.33, Closing at 3.97 - The Dwinnex
scPharmaceuticals GAAP EPS of -$0.41 misses by $0.05, revenue of $3.8M beats by $0.38M - MSN
Does scPharmaceuticals (SCPH) Have the Potential to Rally 291.9% as Wall Street Analysts Expect? - MSN
351,806 Shares in scPharmaceuticals Inc. (NASDAQ:SCPH) Acquired by Bank of Montreal Can - MarketBeat
scPharmaceuticals Inc. (NASDAQ:SCPH) Short Interest Down 15.0% in September - MarketBeat
Holdings of scPharmaceuticals Inc (SCPH) are aligned with the stars - SETE News
Craig Hallum gives a Buy recommendation for scPharmaceuticals Inc (SCPH) - Knox Daily
King Luther Capital Management Corp Purchases 752,005 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - MarketBeat
Investors in scPharmaceuticals (NASDAQ:SCPH) have unfortunately lost 23% over the last year - Yahoo Finance
Rice Hall James & Associates LLC Has $2.16 Million Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) - MarketBeat
scPharmaceuticals Inc [SCPH] Investment Guide: What You Need to Know - Knox Daily
scPharmaceuticals Inc. (NASDAQ:SCPH) Stock Holdings Increased by AIGH Capital Management LLC - MarketBeat
scPharmaceuticals Inc [SCPH] 10% Owner makes an insider purchase of 500,000 shares worth 2.0 million. - Knox Daily
scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
scPharmaceuticals’ $125 Million Senior Secured Term Loan - Global Legal Chronicle
Do investors need to be concerned about scPharmaceuticals Inc (SCPH)? - US Post News
There is no way scPharmaceuticals Inc (SCPH) can keep these numbers up - SETE News
scPharmaceuticals Inc (SCPH) rating initates by Craig Hallum - Knox Daily
Assenagon Asset Management S.A. Boosts Stake in scPharmaceuticals Inc. (NASDAQ:SCPH) - MarketBeat
scPharmaceuticals Inc. to Post Q3 2024 Earnings of ($0.28) Per Share, HC Wainwright Forecasts (NASDAQ:SCPH) - MarketBeat
Craig Hallum’s latest rating for SCPH stock - Knox Daily
After losing 35% in the past year, scPharmaceuticals Inc. (NASDAQ:SCPH) institutional owners must be relieved by the recent gain - Yahoo Finance
scPharmaceuticals (NASDAQ:SCPH) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
scPharmaceuticals stock rated a Buy amid revenue growth - Investing.com
scPharmaceuticals (FRA:2SX) Inventory-to-Revenue : 1.54 (As of Jun. 2024) - GuruFocus.com
Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings - BioCentury
scPharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Brokers Issue Forecasts for scPharmaceuticals Inc.'s Q2 2024 Earnings (NASDAQ:SCPH) - MarketBeat
OrbiMed Advisors LLC buys $2 million in scPharmaceuticals stock By Investing.com - Investing.com South Africa
OrbiMed Advisors LLC buys $2 million in scPharmaceuticals stock - Investing.com India
Earnings call: scPharmaceuticals reports growth and label expansion By Investing.com - Investing.com Australia
Earnings call: scPharmaceuticals reports growth and label expansion - Investing.com
scPharmaceuticals Inc. (NASDAQ:SCPH) Q2 2024 Earnings Call Transcript - Insider Monkey
Q2 2024 EPS Estimates for scPharmaceuticals Inc. (NASDAQ:SCPH) Decreased by Leerink Partnrs - Defense World
scPharmaceuticals Inc (SCPH) Q2 2024 Earnings Call Transcript Hi - GuruFocus.com
SCPH Stock Earnings: scPharmaceuticals Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
scPharmaceuticals Inc Reports Q2 2024 Revenue of $8.1 Million, G - GuruFocus.com
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates - MSN
scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Check Out scPharmaceuticals Inc (SCPH)’s Trade Data Rather Than the Analysts’ Views - SETE News
A Tale of Resilience: scPharmaceuticals Inc Amid Stock Market Turbulence - The InvestChronicle
Latham & Watkins Advises scPharmaceuticals on Growth Financings - Legal Desire News Network
Watkins Advises scPharmaceuticals on Growth Financings - ILW.com
Scpharmaceuticals Inc Azioni (SCPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):